Arditus

Arditus is a clinical-stage biopharmaceutical company focused on developing first-in-class oral therapies for metabolic and inflammatory diseases. The company's lead candidate, ARD-101, is a gut-restricted small molecule TAS2R (bitter taste receptor) agonist designed to stimulate the natural secretion of multiple metabolic hormones, including GLP-1, GLP-2, PYY, and CCK. By targeting the gut's enteroendocrine cells, Arditus aims to provide a potent, systemic metabolic effect with a favorable safety profile due to minimal systemic absorption. The company is currently evaluating its technology in clinical trials for indications such as obesity and Prader-Willi syndrome. Founded by industry veterans, Arditus leverages a unique platform to address significant unmet needs in endocrinology and gastroenterology.